All the news Showing 10 of 294 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources HCV Guidelines: The Standard in Easy-to-Access, Ever-Changing Disease Treatment Healio / 27 February 2018 Ethnic disparities evaporate with DAA treatment of hepatitis C infections ModernMedicine / 06 February 2018 Low skeletal muscle mass improves after successful HCV treatment Healio Hepatology / 22 November 2017 Fatty Liver Common After Direct-Acting Antivirals for Hep C Medscape (requires free registration) / 01 November 2017 Curing hepatitis C with DAAs linked to 71% reduction in liver cancer Liz Highleyman / 30 October 2017 People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, ... Maviret cures most people with HCV genotype 3 and those with cirrhosis Liz Highleyman / 24 October 2017 Glecaprevir and pibrentasvir, the two drugs in the recently approved Maviret co-formulation, demonstrated high sustained response rates for people with chronic hepatitis C virus (HCV) genotype 3 and for people with liver ... Hepatitis C cure leads to improved quality of life Liz Highleyman / 23 October 2017 People who were cured of hepatitis C with direct-acting antivirals (DAAs) had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to study ... Restrictions on free DAA access in many European countries contrary to guidelines and undermine HCV elimination targets, say researchers Michael Carter / 16 October 2017 The restrictions which many European countries impose on free/reimbursed access to hepatitis C virus (HCV) direct-acting antivirals (DAAs) are contrary to guidelines and undermine the World Health Organization (WHO) goal ... Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment Michael Carter / 10 August 2017 For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality rates among people with hepatitis C virus (HCV) monoinfection. The study – ... Direct-acting antivirals successfully treating hepatitis C, says Public Health England Pharmaceutical Journal / 02 August 2017 ← Prev1...34567...30Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive